Wegovy and Erectile Dysfunction: Will Losing Weight Improve Your Erections?

The question most men ask about Wegovy and erections is refreshingly simple: “if I lose the weight, will I get harder erections back?” And unlike a lot of GLP-1 sexual-health questions, this one has a clear directional answer — in obesity-driven erectile dysfunction, meaningful weight loss reliably improves erectile function, and Wegovy is the semaglutide product built to produce the most weight loss. Wegovy is semaglutide 2.4 mg, the dose approved specifically for chronic weight management, and its pivotal STEP-1 trial produced about 14.9% body-weight loss^[10] — about the same as the roughly 15% lifestyle weight loss (mean BMI 36.9 to 31.2) that restored erectile function in about a third of obese men in the landmark Esposito 2004 JAMA randomized trial^[1]. The honest caveat that runs through this entire article: no randomized trial has ever measured erectile function as an endpoint for Wegovy or any semaglutide dose, so the case is built on the weight-loss-to-erection chain, not on a Wegovy ED trial result. Wegovy does not directly cause ED — it is not a labeled adverse reaction — and it is not a magic erection drug either; it is a weight-loss drug, and the erectile benefit rides on the weight coming off. For the cross-drug overview, see the GLP-1 and erectile dysfunction hub; for the “does it cause ED” framing, our does Ozempic cause ED review.

The honest summary

• No Wegovy trial has measured erectile function as an endpoint. The STEP program measured weight, cardiometabolic risk, and safety — not the IIEF-5 or any validated erectile-function instrument. Anyone quoting a precise “Wegovy erection improvement” number is extrapolating from the weight-loss-to-ED chain.
• Wegovy is the semaglutide product that pulls the weight-loss lever hardest. Ozempic (semaglutide for type 2 diabetes) is dosed up to 2.0 mg; Wegovy is dosed to 2.4 mg specifically for weight management. STEP-1 produced −14.9% body weight^[10] — the biggest weight-mediated erectile-function opportunity among semaglutide products.
• Obesity is a leading modifiable cause of ED, and the mechanism is reversible. The Massachusetts Male Aging Study (Feldman 1994^[9]) put obesity, diabetes, hypertension, and cardiovascular disease at the top of the ED correlates list. The damage is mostly vascular endothelial dysfunction plus obesity-driven low testosterone — both of which improve with weight loss.
• The weight-loss-to-erection evidence is strong. Esposito 2004 JAMA^[1] (ED reversal in ~31% vs ~5% control), the Khoo exercise and meal-replacement trials^[4][5], and the Glina 2017 bariatric meta-analysis^[6] all show that meaningful, sustained weight loss improves erectile function. Wegovy's STEP-1 weight loss sits squarely in that effective range.
• Testosterone often rises as the weight comes off. Obesity-associated hypogonadism (Grossmann 2020^[8]) is frequently reversible; the European Male Ageing Study (Camacho 2013^[7]) showed weight loss is associated with a rise in total testosterone, free testosterone, and SHBG.
• Wegovy does not cause ED, but the early weeks can feel different. Nausea, fatigue, and a deep caloric deficit during dose escalation can transiently dampen desire and performance — a comfort effect tied to how weight loss happens, not a fixed drug effect. It usually eases as the dose stabilizes.
• Weight loss does not fix structural or psychogenic ED. Post-prostatectomy, Peyronie's, neurogenic, and severe venous-leak ED are mechanical problems; medication-induced and psychogenic ED need their own workup. Wegovy is a parallel intervention there, not the fix.

Why Wegovy is the semaglutide product most likely to move your erections

Wegovy and Ozempic are the same molecule — semaglutide — but for an erectile-function question they are not the same product. Ozempic is dosed up to 2.0 mg for type 2 diabetes; Wegovy is dosed to 2.4 mg specifically for chronic weight management. Because the erectile benefit of any GLP-1 runs almost entirely through weight loss, the product that produces the most weight loss is the one most likely to move erections — and among semaglutide products, that is Wegovy. In STEP-1, semaglutide 2.4 mg produced about 14.9% body-weight loss at 68 weeks^[10]; the lower diabetes doses produce less. This does not mean Wegovy has a special erection mechanism that Ozempic lacks — it means the weight-mediated effect, which is the whole ballgame here, is more pronounced on the higher, weight-loss-optimized dose. If you take lower-dose semaglutide, the direction is the same, just smaller.

The one product that beats Wegovy on raw weight-loss magnitude is tirzepatide — Zepbound produced about −20.9% in SURMOUNT-1^[11] — so if the lever is weight loss, tirzepatide pulls it even harder. But within the semaglutide family, Wegovy is the erectile-function front-runner by dose.

Why obesity drives ED in the first place

An erection is a vascular event. Sexual stimulation releases nitric oxide from the cavernosal endothelium and nerves; nitric oxide relaxes vascular smooth muscle; the cavernosal sinusoids fill with arterial blood; venous outflow is compressed; the penis becomes erect. Every step depends on a healthy endothelium and an adequate testosterone level. Obesity damages this chain in three converging ways:

1. Endothelial dysfunction. Obesity-driven insulin resistance and chronic low-grade inflammation cut endothelial nitric-oxide bioavailability — the same mechanism that drives early atherosclerosis. The penile arteries are small (~1–2 mm), so they show endothelial dysfunction before the coronary arteries do. This is why vascular ED is an early warning sign for occult coronary disease.
2. Obesity-associated low testosterone. Adipose tissue expresses aromatase, which converts testosterone to estradiol, and obesity suppresses hypothalamic GnRH pulsatility. The result is measurably lower total and free testosterone in obese men than in lean peers — “functional” or “late-onset” hypogonadism (Grossmann 2020^[8]).
3. Co-occurring vascular disease. Type 2 diabetes, hypertension, dyslipidemia, and sleep apnea cluster with obesity and independently damage the endothelium. Feldman's MMAS data^[9] placed diabetes, hypertension, and cardiovascular disease at the top of the ED correlates list.

The good news buried in that list is that these mechanisms are mostly reversible. That is exactly why the weight-loss intervention works — and why a drug like Wegovy, which produces large sustained weight loss, is expected to help.

The weight-loss-to-erection evidence

The single most-cited piece of evidence is the Esposito 2004 JAMA randomized controlled trial^[1]. In 110 obese men with mild-to-moderate ED and no overt cardiometabolic disease, a two-year Mediterranean-pattern diet plus structured exercise lowered mean BMI from 36.9 to 31.2 (roughly 15% of body weight) versus 36.4 to 35.7 in controls, and restored erectile function (IIEF-5 back to a non-ED range) in about 31% of the intervention arm versus about 5% of controls. The dietary pattern matters on its own terms too: the Mediterranean diet is repeatedly linked to lower rates of sexual dysfunction (Giugliano 2006^[2]) and, in men with type 2 diabetes, greater adherence to it tracks with less erectile dysfunction (Giugliano 2010^[3]).

Two follow-up trials by Khoo and colleagues extend the finding to the mechanism level. Khoo 2013 (J Sex Med^[4]) randomized obese men to low- versus high-volume exercise and found dose-dependent improvements in IIEF-5 and testosterone. Khoo 2014 (Int J Impot Res^[5]) compared meal-replacement caloric restriction with a reduced-fat diet; the larger weight loss produced greater gains in IIEF-5, flow-mediated dilatation (a direct endothelial-function measure), and testosterone. The takeaway for the GLP-1 era: it is the size of the sustained caloric deficit and weight loss that improves erectile function, not the particular route used to get there.

Bariatric surgery anchors the top of the dose-response. The Glina 2017 systematic review and meta-analysis (Sex Med Rev^[6]) selected seven studies and, pooling two of them, found a 5.66-point rise in the five-item IIEF score after bariatric surgery (and a 4.10-point rise in the IIEF erectile-function domain across three studies). Surgery typically produces ~25–35% total body-weight loss — more than Wegovy — but the mechanism is identical.

Where Wegovy's weight loss lands on that dose-response

Lining the interventions up by weight-loss magnitude makes the Wegovy expectation concrete. The Esposito lifestyle program cut mean BMI from 36.9 to 31.2 (roughly 15% of body weight) and reversed ED in ~31% of men. Wegovy in STEP-1 produced 14.9%^[10] — essentially the same magnitude, achieved more reliably because a weekly injection does not depend on two years of dietary willpower. Tirzepatide (SURMOUNT-1, −20.9%^[11]) sits higher; bariatric surgery (~30%) higher still. Since erectile improvement scales roughly with weight-loss magnitude across this literature, the reasonable expectation for an obese man with vascular-pattern ED who loses ~15% of his body weight on Wegovy and keeps it off for 12–24 months is measurable erectile improvement — landing between the Esposito lifestyle result and the bariatric result. The evidence base is not yet at the “here is the randomized Wegovy number” level; it is inference from a well-established chain.

If Wegovy or a semaglutide alternative is right for you — top vetted providers

Testosterone: the hormonal half of the benefit

Erectile function is not only vascular — testosterone maintains the machinery, and obesity lowers it. Because adipose tissue aromatizes testosterone to estradiol, obese men run measurably lower total and free testosterone than lean peers. The European Male Ageing Study longitudinal data (Camacho 2013^[7]) followed 2,395 men for about 4.4 years: weight loss was associated with a proportional rise in total testosterone and SHBG and weight gain with a proportional fall, while free testosterone changed significantly only in men who lost or gained 15% or more of their weight. Grossmann 2020^[8] is the modern review of this reversible, obesity-associated hypogonadism.

The practical implication for a Wegovy user: if you also have a confirmed low morning total testosterone, the weight loss itself is one of the few interventions that can move it back toward range without exogenous testosterone. That is worth discussing with a clinician before starting testosterone replacement, because functional hypogonadism in an obese man is often reversible with weight loss alone. For the deeper dive, see our GLP-1s, testosterone, and male fertility review.

Practical expectations and timing

• Think in months, not weeks. The Esposito trial measured at 2 years; the Khoo exercise trial at 24 weeks. Erectile improvement follows accumulated, sustained weight loss — there is no evidence that a few weeks of weight loss reverses ED.
• Ride out the early titration dip. If desire or performance dips during your worst nausea-and-fatigue weeks, that is the most common and most self-limited scenario. Reassess once the dose is stable and weight loss is underway.
• Protect lean mass and energy. Adequate protein, resistance training, and hydration support both testosterone and erectile function — do not under-eat protein just because appetite is low. See our exercise-pairing guide.
• A PDE5 inhibitor can bridge the gap. Sildenafil and tadalafil have no pharmacokinetic interaction with semaglutide (peptide drugs are not CYP3A4 substrates). The absolute contraindication for PDE5 inhibitors remains nitrates — independent of Wegovy.
• Rule out the other usual suspects. Blood pressure, blood sugar, sleep apnea, alcohol, smoking, mood, and medications (thiazides, beta-blockers, finasteride, SSRIs) all affect erections independent of any GLP-1.

When weight loss is the wrong tool

• Post-radical-prostatectomy ED — cavernosal nerve injury is structural; weight loss does not regenerate the neurovascular bundles.
• Peyronie's disease — fibrous plaque in the tunica albuginea; weight loss has no documented effect on the plaque.
• Neurogenic ED (spinal-cord injury and others) — weight loss does not restore lost autonomic pathways.
• Severe venous-leak ED — a mechanical failure of the veno-occlusive mechanism, not a metabolic one.
• Medication-induced ED — SSRIs, finasteride, and some beta-blockers; the first step is addressing the offending drug with the prescriber.
• Psychogenic ED — situational (morning and masturbatory erections intact, partnered erections difficult), common in younger men; behavioral therapy and anxiety treatment, not weight loss, are the interventions.

What we still don't know

• No published Wegovy or semaglutide trial has used the IIEF-5 or any validated erectile-function instrument as a pre-specified endpoint. The case for benefit is inferential.
• Whether erectile improvement persists after stopping Wegovy is unstudied. Weight regain after GLP-1 cessation is well documented; whether erectile gains regress in parallel is unknown but should be assumed.
• A potential direct effect of GLP-1 signaling on endothelial function, independent of weight loss, has been suggested in small studies but not quantified in an erectile-function endpoint.
• The relative contribution of the vascular versus the testosterone pathway to any Wegovy-driven erectile improvement has not been disentangled.

Bottom line

• Wegovy is the 2.4 mg weight-management dose of semaglutide, and in obesity-driven ED, weight loss reliably improves erectile function. Wegovy's STEP-1 weight loss (−14.9%^[10]) matches the Esposito lifestyle intervention^[1] that reversed ED in ~31% of obese men.
• Among semaglutide products, Wegovy pulls the weight-loss lever hardest, so it offers the biggest weight-mediated erectile opportunity — tirzepatide^[11] and bariatric surgery^[6] sit higher on the same dose-response.
• The mechanism is reversal of endothelial dysfunction (Khoo^[4][5]) and obesity-driven low testosterone (Camacho^[7], Grossmann^[8]); obesity sits atop the ED correlates list (Feldman^[9]), and a Mediterranean dietary pattern independently helps^[2][3].
• Wegovy does not cause ED. An early-titration dip, if it happens, is a comfort effect of the deficit and nausea, not a fixed drug effect.
• Weight loss does not fix structural or psychogenic ED. Any new or progressive ED warrants a workup — ED can be an early warning sign of cardiovascular disease.

New or worsening erectile dysfunction warrants evaluation by a primary-care clinician or urologist, including a morning total testosterone, fasting glucose or HbA1c, lipid panel, blood-pressure assessment, medication review, and sleep-apnea screening. ED can be an early warning sign of occult coronary artery disease. Sildenafil, tadalafil, and vardenafil are contraindicated in men taking any form of nitrate. Erectile dysfunction is not a listed adverse reaction in the FDA prescribing information for Wegovy. Do not start, stop, or change any prescription medication based on this article.